ArticleRevista panamericana de salud publica = Pan American journal of public health2024
[Microplanning as a tool to strengthen the National Immunization Program in BrazilLa microplanificación como herramienta para fortalecer el Programa Nacional de Inmunizaciones en Brasil].
Article in Revista panamericana de salud publica = Pan American journal of public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Risk of reintroduction of vaccine-preventable diseases in the state of São Paulo, Brazil.Revista de saude publica · 2026Article
- Microplanning workshops for high-quality vaccination in Brazil: an experience report, 2023.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To measure the variation in number of doses, vaccination coverage (VC) of administered vaccines, and number of municipalities that achieved the VC target in Brazil with the implementation of microplanning for high-quality vaccination activities (HQVA) and decentralized multivaccination actions. Methods: This quasi-experimental study used data from the National Live Birth Information System, the National Immunization Program Information System, and the National Health Data Network. The number of doses of hepatitis A (HA), meningococcal conjugate-C, oral poliomyelitis, 10-valent pneumococcal, diphtheria-tetanus-pertussis (DTP), and measles-mumps-rubella (MMR) vaccines administered to children under 2 years of age in 2022 (pre-microplanning) and 2023 (post-microplanning) was estimated. VC and the number of municipalities that achieved the VC target were also estimated. Results: In 2022, 13 253 873 doses of the selected vaccines were recorded. In 2023, 13 570 346 doses were administered. An increase in VC was observed, especially for the DTP vaccine (increase > 12%); and for the HA and MMR vaccines (increase close to 10%). The number of municipalities that reached the VC target grew in 2023 (increase of 51.98% for MMR and 7.77% for the meningococcal vaccine). Conclusion: Microplanning strengthened routine immunization and was a timely measure to address situations of declining VC. This favorable outcome also highlights the importance of continuing and expanding these actions to achieve and maintain positive results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.